Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Vanderbilt University

Status: Completed

Conditions: Ovarian Cancer

Study type: Observational

Funder types: Other; Industry; NIH

Identifiers

NCT01096394

VU-VICC-GYN-0917 (Other Identifier)

P30CA068485 (U.S. NIH Grant/Contract)

IRB# 090075 (Other Identifier)

090075

Details and patient eligibility

About

RATIONALE: Collecting and storing samples of tumor tissue and ascites fluid from patients to test in the laboratory may help the study of cancer.

PURPOSE: This pre-clinical research study is collecting tissue samples and ascites fluid from patients with stage III or stage IV ovarian/primary peritoneal/fallopian tube epithelial cancer.

Full description

OBJECTIVES:

• To generate a translational ovarian cancer model using tumor tissue and cells from patients with stage III-IV ovarian/primary peritoneal/fallopian tube epithelial cancer for drug response and development.

OUTLINE: Tissue and fluid samples are collected at the time of surgery or paracentesis and used in laboratory experiments and in animal models. Health data is collected from patient medical records before, during, and after surgery.

After surgery, patients are followed up for 5 years.

Enrollment: 20 patients

Sex: Female

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

INCLUSION:

• Females age 18-80 with a diagnosis of Stage III-IV ovarian cancer, primary fallopian tube, or primary peritoneal papillary serous carcinoma and scheduled treatment for epithelial ovarian malignancies.

EXCLUSION:

• Patients with less than Stage III epithelial ovarian cancer, primary fallopian tube, or primary peritoneal papillary serous carcinoma
• Patients who have received prior chemotherapy
• Patients who have nonepithelial ovarian cancer, primary fallopian tube, or primary peritoneal carcinoma
• Patients who have malignancy other than ovarian cancer, primary fallopian tube, or primary peritoneal carcinoma

Trial design

20 participants in 1 patient group

Ovarian cancer

Description:

Patients with presumed Stage III-IV ovarian, primary fallopian tube, or primary peritoneal papillary serous carcinoma.